These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 35776657)

  • 21. Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA.
    Kaseb AO; Sánchez NS; Sen S; Kelley RK; Tan B; Bocobo AG; Lim KH; Abdel-Wahab R; Uemura M; Pestana RC; Qiao W; Xiao L; Morris J; Amin HM; Hassan MM; Rashid A; Banks KC; Lanman RB; Talasaz A; Mills-Shaw KR; George B; Haque A; Raghav KPS; Wolff RA; Yao JC; Meric-Bernstam F; Ikeda S; Kurzrock R
    Clin Cancer Res; 2019 Oct; 25(20):6107-6118. PubMed ID: 31363003
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma.
    Joseph NM; Tsokos CG; Umetsu SE; Shain AH; Kelley RK; Onodera C; Bowman S; Talevich E; Ferrell LD; Kakar S; Krings G
    J Pathol; 2019 Jun; 248(2):164-178. PubMed ID: 30690729
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genomic Landscape of Liquid Biopsy for Hepatocellular Carcinoma Personalized Medicine.
    Moldogazieva NT; Zavadskiy SP; Terentiev AA
    Cancer Genomics Proteomics; 2021; 18(3 Suppl):369-383. PubMed ID: 33994362
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted Next-Generation Sequencing Combined With Circulating-Free DNA Deciphers Spatial Heterogeneity of Resected Multifocal Hepatocellular Carcinoma.
    Lin J; Zhao S; Wang D; Song Y; Che Y; Yang X; Mao J; Xie F; Long J; Bai Y; Yang X; Zhang L; Bian J; Lu X; Sang X; Pan J; Wang K; Zhao H
    Front Immunol; 2021; 12():673248. PubMed ID: 34211467
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeted Next-Generation Sequencing of Plasma Cell-Free DNA in Korean Patients with Hepatocellular Carcinoma.
    Chae H; Sung PS; Choi H; Kwon A; Kang D; Kim Y; Kim M; Yoon SK
    Ann Lab Med; 2021 Mar; 41(2):198-206. PubMed ID: 33063681
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessments of TP53 and CTNNB1 gene hotspot mutations in circulating tumour DNA of hepatitis B virus-induced hepatocellular carcinoma.
    Kumar S; Nadda N; Quadri A; Kumar R; Paul S; Tanwar P; Gamanagatti S; Dash NR; Saraya A; Shalimar ; Nayak B
    Front Genet; 2023; 14():1235260. PubMed ID: 37593116
    [No Abstract]   [Full Text] [Related]  

  • 27. The use of minimally invasive biomarkers for the diagnosis and prognosis of hepatocellular carcinoma.
    Trevisan França de Lima L; Broszczak D; Zhang X; Bridle K; Crawford D; Punyadeera C
    Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188451. PubMed ID: 33065194
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preferred end coordinates and somatic variants as signatures of circulating tumor DNA associated with hepatocellular carcinoma.
    Jiang P; Sun K; Tong YK; Cheng SH; Cheng THT; Heung MMS; Wong J; Wong VWS; Chan HLY; Chan KCA; Lo YMD; Chiu RWK
    Proc Natl Acad Sci U S A; 2018 Nov; 115(46):E10925-E10933. PubMed ID: 30373822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification.
    Calderaro J; Couchy G; Imbeaud S; Amaddeo G; Letouzé E; Blanc JF; Laurent C; Hajji Y; Azoulay D; Bioulac-Sage P; Nault JC; Zucman-Rossi J
    J Hepatol; 2017 Oct; 67(4):727-738. PubMed ID: 28532995
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preoperative serum ctDNA predicts early hepatocellular carcinoma recurrence and response to systemic therapies.
    Fu Y; Yang Z; Hu Z; Yang Z; Pan Y; Chen J; Wang J; Hu D; Zhou Z; Xu L; Chen M; Zhang Y
    Hepatol Int; 2022 Aug; 16(4):868-878. PubMed ID: 35674872
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TERT promoter mutated circulating tumor DNA as a biomarker for prognosis in hepatocellular carcinoma.
    Oversoe SK; Clement MS; Pedersen MH; Weber B; Aagaard NK; Villadsen GE; Grønbæk H; Hamilton-Dutoit SJ; Sorensen BS; Kelsen J
    Scand J Gastroenterol; 2020 Dec; 55(12):1433-1440. PubMed ID: 33103505
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liquid biopsy derived circulating tumor cells and circulating tumor DNA as novel biomarkers in hepatocellular carcinoma.
    Temraz S; Nasr R; Mukherji D; Kreidieh F; Shamseddine A
    Expert Rev Mol Diagn; 2022 May; 22(5):507-518. PubMed ID: 35758097
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted Molecular Profiling of Circulating Cell-Free DNA in Patients With Advanced Hepatocellular Carcinoma.
    Cowzer D; White JB; Chou JF; Chen PJ; Kim TH; Khalil DN; El Dika IH; Columna K; Yaqubie A; Light JS; Shia J; Yarmohammadi H; Erinjeri JP; Wei AC; Jarnagin W; Do RKG; Solit DB; Capanu M; Shah RH; Berger MF; Abou-Alfa GK; Harding JJ
    JCO Precis Oncol; 2023 Sep; 7():e2300272. PubMed ID: 37769223
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Somatic Mutations in Circulating Cell-Free DNA and Risk for Hepatocellular Carcinoma in Hispanics.
    Jiao J; Sanchez JI; Thompson EJ; Mao X; McCormick JB; Fisher-Hoch SP; Futreal PA; Zhang J; Beretta L
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299031
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prediction of the prognosis of advanced hepatocellular carcinoma by TERT promoter mutations in circulating tumor DNA.
    Hirai M; Kinugasa H; Nouso K; Yamamoto S; Terasawa H; Onishi Y; Oyama A; Adachi T; Wada N; Sakata M; Yasunaka T; Onishi H; Shiraha H; Takaki A; Okada H
    J Gastroenterol Hepatol; 2021 Apr; 36(4):1118-1125. PubMed ID: 32830343
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma.
    Xu RH; Wei W; Krawczyk M; Wang W; Luo H; Flagg K; Yi S; Shi W; Quan Q; Li K; Zheng L; Zhang H; Caughey BA; Zhao Q; Hou J; Zhang R; Xu Y; Cai H; Li G; Hou R; Zhong Z; Lin D; Fu X; Zhu J; Duan Y; Yu M; Ying B; Zhang W; Wang J; Zhang E; Zhang C; Li O; Guo R; Carter H; Zhu JK; Hao X; Zhang K
    Nat Mater; 2017 Nov; 16(11):1155-1161. PubMed ID: 29035356
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of oncogenic mutations in paired circulating tumor DNA and circulating tumor cells in patients with hepatocellular carcinoma.
    Ge Z; Helmijr JCA; Jansen MPHM; Boor PPC; Noordam L; Peppelenbosch M; Kwekkeboom J; Kraan J; Sprengers D
    Transl Oncol; 2021 Jul; 14(7):101073. PubMed ID: 33915518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of circulating tumor DNA in hepatocellular and pancreatic carcinomas.
    Dhayat SA; Yang Z
    J Cancer Res Clin Oncol; 2020 Jul; 146(7):1625-1645. PubMed ID: 32338295
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genomic characterization of early-stage hepatocellular carcinoma patients with Hepatitis B using circulating tumor DNA.
    Lin D; Luo R; Ye Z; Wei Q; Bae H; Juon HS; Hann HW; Posey J; Wang C
    Clin Res Hepatol Gastroenterol; 2023 Aug; 47(7):102161. PubMed ID: 37307947
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab.
    Mohamed YI; Lee SS; Demir T; Chamseddine S; Hu ZI; Xiao L; Elsayes K; Morris JS; Wolff RA; Hiatia R; Qayyum A; Rashid A; Duda DG; Yao JC; LaPelusa M; Koay EJ; Mahvash A; Al Azzam A; Dumbrava EE; Hassan M; Amin HM; Kaseb AO
    Cancer Biomark; 2024; 41(1):83-91. PubMed ID: 39269823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.